BioSpace News Archive

Stoke Therapeutics, Inc. today announced that presentations related to the Company’s work in Dravet syndrome will be presented at the American Epilepsy Society (AES) 2023 Annual Meeting, taking place December 1 – 5, in Orlando, Florida.

CytoDyn Inc., a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced the appointment of Dr. Jacob Lalezari as interim CEO, effective November 17, 2023.

Nemaura Medical Inc. is pleased to announce the execution of a strategic agreement for a $10 million credit facility which is expected to support the Company’s strategic growth plans.

NanoVibronix, Inc. announced that on November 20, 2023, the Company received official notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the minimum stockholders’ equity requirement of $2.5 million.

IGC Pharma, Inc. announced a Master Cooperation Agreement with the University of Los Andes for the development and adoption of generative AI solutions into the Company’s drug identification, development, and clinical trial processes.

Napo Pharmaceuticals, a Jaguar Health, Inc. family company, announced that the company has not yet been provided with results from the company’s GCP vendors supporting Napo’s pivotal Phase 3 OnTarget trial.

Neogen Corporation (NASDAQ: NEOG) announced today that the Company will participate in the Piper Sandler 35th Annual Healthcare Conference in New York City on Thursday, November 30, 2023.

MindBio Therapeutics Corp. is pleased to report two of its team members have been honoured with industry leading awards.

Gain Therapeutics, Inc. today announced the pricing of an underwritten public offering of 2,213,044 shares of its common stock and warrants to purchase up to an aggregate of 1,106,522 shares of its common stock at a combined public offering price of $2.005 per share and accompanying warrant.

NS Pharma, Inc. announced the launch of Duchenne Heroes a program created to raise awareness and champion the voices of people affected by Duchenne muscular dystrophy.